for females ages 18 years and up (full criteria)
study started
completion around
Principal Investigator
by Sanaz Memarzadeh (ucla)
Headshot of Sanaz Memarzadeh
Sanaz Memarzadeh



This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

Official Title

ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)


Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response, PARP inhibitor, PARPi, HRD, ATHENA, homologous recombination, DNA repair, LOH, DNA defect, DNA anomaly, Rucaparib, Nivolumab, PD-1, Immuno-, oncology, Tumor, mutational, burden, BRCA, First-line, Primary Therapy, Primary Treatment, Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Fallopian Tube Neoplasms


You can join if…

Open to females ages 18 years and up

  • Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or following neoadjuvant chemotherapy (interval debulking)
  • Completed first-line platinum-based chemotherapy and surgery with a response, in the opinion of the Investigator
  • Sufficient tumor tissue for planned analysis
  • ECOG performance status of 0 or 1
  • Patients must be 20 years of age to consent in Japan, Taiwan and South Korea; in all other participating countries patients must be 18 years of age to consent

You CAN'T join if...

  • Pure sarcomas or borderline tumors or mucinous tumors
  • Active second malignancy
  • Known central nervous system brain metastases
  • Any prior treatment for ovarian cancer, other than the first-line platinum regimen
  • Evidence of interstitial lung disease or active pneumonitis
  • Active, known or suspected autoimmune disease
  • Condition requiring active systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications


  • UCLA Women's Health Clinical Research Unit
    Los Angeles California 90095 United States
  • John Muir Clinical Research Center
    Concord California 94520 United States
  • Kaiser Permanente Northern California
    San Francisco California 94589 United States

Lead Scientist at University of California Health

  • Sanaz Memarzadeh (ucla)
    At the G.O. Discovery Lab directed by Sanaz Memarzadeh, we are on a mission to help patients with gynecologic cancers. Our research is focused on two understudied and aggressive epithelial gynecologic cancers that affect thousands of women each year: ovarian and endometrial carcinomas.


in progress, not accepting new patients
Start Date
Completion Date
pharmaand GmbH
Phase 3 research study
Study Type
Expecting 1000 study participants
Last Updated